Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab

Severe eosinophilic asthma (SEA) has been associated with T-helper type 2 (Th2) inflammatory response. A good understanding of T cell functions in is important for therapy, especially the choice biological treatments severe cases. Mepolizumab, an IL-5 antagonist, indicated treatment asthma. Regulatory cells (Tregs) suppress inflammation by secreting cytokines that inhibit Th2 proliferation. We investigated peripheral Treg, CD4, CD8, CD19 and NK percentages their relationship to clinical functional parameters, including eosinophils, before after anti-IL5 treatment. Subjects were 14 adult SEA patients (9 male, 54.1 ± 11.6 years), treated mepolizumab, 10 controls. (CD4 CD8), CD19, Tregs evaluated flow cytometry. Comparison lung function parameters mepolizumab (T0 T1) showed increase FEV1, FEV1/FVC ratio a reduction blood eosinophil percentages. CD8 CD16/56+CD3+ significantly higher than controls (P = .04 P .03, respectively). decrease CD45+, + was observed between T0 T1 .02, .04, significant Treg .0001) recorded T1. Mepolizumab therapy found modulate immune response, restoring balance SEA.